Phase I Study of Eltrombopag for Promoting Thrombopoiesis After Total Body Irradiation
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Patients who undergo total body irradiation (TBI) for stem cell transplantation have
prolonged periods of low counts of specific blood cells called platelets. These low platelets
counts can cause bleeding and infection. Thus far, no drug is available for use to speed the
recovery of platelets, and therefore transfusions are often necessary.
The purpose of this study is to test the safety of a drug called eltrombopag in patients who
have received TBI. The investigators want to find out what effects, good or bad, it has on
people with low platelet counts due to treatment with TBI. The investigators will also be
testing how well eltrombopag may work at different doses and determine if this drug speeds up
the recovery of the platelets.